Have you ever had a sudden, relentless itch soon after you stopped taking your daily allergy medication? In mid-May, the U.S. Food and Drug Administration (FDA) issued a surprising warning- individuals who stop taking long-term usual over-the-counter antihistamines such as Zyrtec (cetirizine) or Xyzal (levocetirizine) may develop a severe, generalized itching a condition medically referred to as pruritus. Although uncommon, this reaction can be severe enough to seek medical attention, and it is an indication of how important it is to be educated prior to discontinuing these popular drugs.

Tens of millions of Americans use cetirizine or levocetirizine every year to manage seasonal sneezes or chronic hives. In 2022 alone, over 62.7 million OTC units of these antihistamines were sold, and another 26.8 million were prescribed by outpatient pharmacies. However, between April 2017 and July 2023, the FDA reported 209 worldwide cases of intense itching after sudden stopping of these drugs—180 for Zyrtec, 27 for Xyzal, and two each for both. There were 197 cases in the United States, though experts assume this could be a low estimate because not all reactions are reported to the authorities.

"For now, we want to inform the public of this risk," the FDA said on May 16, 2025, stressing that although pruritus upon discontinuation of these drugs is rare compared with their widespread use, the agency is revising labeling and requesting manufacturers to place a warning on OTC Drug Facts labels.

What Is Pruritus?

Pruritus is the medical term for itching and may result from many causes, from dry skin to systemic disease. The Cleveland Clinic states that pruritus results when nerve endings in the skin are stimulated excessively by inflammatory pathways, allergens, or neurological disease. What is interesting about the FDA warning is that patients who had the reaction had no history of itching prior to starting their antihistamine treatment and the symptom would usually appear within days of ceasing the drug after months or even years of daily intake.

"Once in a while, this occurs, and Opella maintains the safety of Xyzal when taken as instructed," an Opella spokesperson told PEOPLE magazine, emphasizing that millions of people get along fine with these medications. A representative for Zyrtec, contacted by phone, also confirmed the drug's decades-long track record for safety but had no further information regarding the FDA alert.

Why Does Stopping Antihistamines Trigger Severe Itching?

Scientists continue to explore the exact mechanism. One hypothesis is that chronic antihistamine use can desensitize the histamine receptors or affect nerve conduction pathways. When the drug is discontinued, the receptors might become hyperresponsive and unleash a trail of itch-inducing chemicals into the skin. Since histamine also helps regulate nerve and inflammation functions, sudden withdrawal can unleash a rebound effect much more severe than typical dryness or superficial irritation.

Dr. Karen Liu, an independent dermatologist and not involved in the FDA review, says, "Antihistamines quiet histamine-induced inflammation. If you all of a sudden take that blockage away after extended use, the body's normal histamine reaction can spike, causing severe pruritus."

Who Is at Risk and What to Do Next?

Although the majority of patients who experienced pruritus were taking Zyrtec or Xyzal daily for a minimum of three months, some had symptoms only after a few weeks of usage. Due to this inconsistency, the FDA recommends anyone considering prolonged antihistamine therapy to have the benefits and risks reviewed with their physician. If you experience violent itching several days after stopping cetirizine or levocetirizine, call your doctor at once.

No formal treatments for withdrawal-induced pruritus have been sanctioned. Yet patients say restarting the antihistamine usually takes care of symptoms, and some find that slowing down the dose instead of just quitting works for them. "Physicians should balance the advantages of continuing therapy against the risk of rebound scratching," suggests Dr. Liu. Any restart or taper plan should be orchestrated by a physician.

Warning Amid Intensifying Allergy Seasons

Experts point out that allergy incidence is increasing, partly due to climate change, which lengthens pollen seasons and doubles airborne allergens. As increasing numbers of individuals become dependent on daily antihistamines for symptom management, knowing about infrequent but dangerous side effects becomes critical. The FDA's actions to revise prescribing labels and over-the-counter warnings in line with a new guidance reflect a balance between transparency and patient protection and not discouraging therapeutic use.

"Meanwhile, patients should be alert," the FDA said. "If more information becomes available, we will follow up." This changing advice reflects the subtleties of long-term drug use—especially with drugs once assumed to be harmless.

For millions, Zyrtec and Xyzal provide invaluable relief from itching, sneezing, and congestion. Yet this new warning is a reminder that no medication is entirely free of risk, especially when discontinuing after extended use. Before beginning—or stopping—long-term antihistamine therapy, consider these steps:

• Ask your doctor how long you should remain on daily antihistamines based on your allergy severity and lifestyle.
• Be mindful of the risk for intense itching and the availability to taper instead of abruptly stopping.
• Inform health professionals immediately if you develop unexplained or severe itching when you stop your allergy medication.
• Check for new Drug Facts labels on OTC medications and examine prescribing labels on prescription forms.

Though serious post-discontinuation pruritus is uncommon, vigilance equips patients and doctors alike to proceed with allergy treatment knowing what to expect. As manufacturers, regulatory agencies, and medical professionals work together to update safety information, individuals are enabled to make well-informed decisions—so relief from summer discomfort does not yield to an unwanted and unpleasant reaction.

Danish pharma giant Novo Nordisk has once again reduced the prices of its blockbuster drugs Ozempic and Wegovy in India. The strategic move is aimed at staying ahead of the entry of the low-cost generic competition in the country.

Starting today, the Ozempic price in India will be cut by 36 percent, while Wegovy has seen a steeper 48 percent reduction — limiting the base price below Rs 6,000 per month.

While Ozempic is available in three dose strengths of 0.25 mg, 0.5 mg, and 1 mg in India, Wegovy has five dose strengths.

Ozempic's and Wegovy's lowest doses of 0.25 ⁠mg will now be priced at Rs 1,415 for a weekly shot from Rs 2,200 and Rs 2,712 earlier, respectively, Novo Nordisk India said in a statement on Tuesday.

The average price reduction across doses is 23.8 percent for Ozempic and 27 percent for Wegovy, it added.

Speaking to the media, Novo Nordisk stated that the price cut will benefit a large section of people with diabetes and obesity in India.

The generic weight loss drugs will open up a huge customer base, especially in India, with a high burden of diabetes and obesity.

Novo first slashed Wegovy's price for the first time by up to 37 percent from its launch price last year.

In addition to the entry of generics, the launch of rival Eli Lilly's blockbuster diabetes and obesity drug Mounjaro in India in 2025.

Also read: Semaglutide Becomes Cheap In India: A Gamechanger Or Health Gamble?

Entry Of Generics In India

Soon after the end of Novo Nordisk's patent on semaglutide, on March 20, a host of companies in India launched generic versions of Ozempic.

This includes NATCO Pharma's Semanat and Semafull, priced at Rs 1,290 per month and Rs 1,750 — about 90 per cent cheaper than Ozempic, costing Rs 8,800 per month.

Eris Lifesciences also announced its plans to launch a multi-dose vial under the brand name Sundae at the same price.

Dr. Reddy’s Laboratories, Sun Pharmaceutical Industries, and Glenmark Pharmaceuticals have also launched their generic versions of semaglutide.

Dr. Reddy’s Obeda is priced at Rs 4,200 per month, available in 2 mg and 4 mg strengths.

Sun Pharmaceutical Industries will sell under the brand names Noveltreat (doses ranging from Rs 900) and Sematrinity (doses ranging from Rs 750). Meanwhile, Glenmark’s GLIPIQ vials range from Rs 325 to Rs 440 per week.

Zydus Lifesciences has also announced the launch of its generic version of semaglutide injection under the brand names SEMAGLYNTM, MASHEMATM, and ALTERMET. The average monthly cost of the treatment will be about Rs 2,200, the company said in a statement.

How Does Semaglutide Work?

Semaglutide works as a GLP-1 receptor agonist that mimics the GLP-1 hormone to regulate appetite and blood sugar. It slows gastric emptying and makes you feel fuller longer. It also signals the brain to reduce hunger and cravings, and triggers the pancreas to release insulin when blood sugar is high.

Also read: This Pill Is More Effective For Weight Loss Than Ozempic, Scientists Say

They work by increasing insulin release in a glucose-dependent manner, decreasing the liver's production of glucagon, and slowing down the emptying of the stomach, which helps lower blood sugar levels after a meal. They also act on the brain to suppress appetite and increase feelings of fullness, leading to reduced calorie intake.

In people with type 2 diabetes, notes Harvard Health, the body's cells are resistant to the effects of insulin and the body does not produce enough insulin, or both. This is when GLP-1 agonists stimulate the pancreas to release insulin and suppress the release of another hormone called glucagon.

These drugs also act in the brain to reduce hunger and act on the stomach to delay emptying, so you feel full for a longer time. These effects can lead to weight loss, which can be an important part of managing diabetes.

Health officials in the US have issued a risk of leptospirosis — a bacterial illness — in Hawaii, after the “Kona low” storm floods.

The Hawaii Department of Health (DOH) and the Hawaiian Humane Society (HHS) have urged residents and recovery workers to monitor for signs of leptospirosis that can affect both people and pets.

Leptospirosis is caused by bacteria Leptospira, which are carried in the urine of infected animals, including rats, mice, mongoose, livestock, and dogs.

The disease can spread via the urine of infected animals and can enter the human body through broken skin or through the mouth, nose, or eyes.

“Hawaii already has among the highest rates of leptospirosis in the country due to its warm, wet climate,” said HHS and DOH in a joint statement.

“Flooding events like the recent Kona low storm can dramatically increase exposure risk by spreading contaminated soil and water across a broad area,” it added.

The agency urged people to check out symptoms in pets, such as fever, decreased appetite, vomiting, diarrhea, and muscle soreness, and get medical help.

The risk of Leptospirosis outbreak is common after a storm, because the dead animals are likely to spread the bacteria. Further, flooding also forces rodents out of their burrows, leading them into homes, shelters, and debris piles where they shed bacteria more easily.

What Is Leptospirosis?

Leptospirosis is one of the most prevalent zoonotic diseases worldwide, often linked to poor sanitation and agricultural practices that involve contact with animals or contaminated water.

The bacteria can survive in contaminated water or soil for weeks to months, primarily spreading through the urine of infected animals.

Also read: With Rising Temperatures A Major Rat Infestation Is Taking Over The World- Why Is This A Health Hazard?

Humans can contract the disease through direct contact with infected urine or through contaminated food, water, or soil.

There are two main forms of leptospirosis: icteric leptospira, which presents with jaundice, and anicteric leptospira, a milder variant without jaundice. Leptospirosis can also manifest as Weil's disease, a severe complication.

What Are Symptoms Of Leptospirosis in humans?

Symptoms typically develop 2 to 30 days after exposure and can range from mild to severe. Initial signs often include

• high-grade fever,
• red eyes (conjunctival suffusion),
• calf tenderness,
• headache,
• dry cough,
• nausea,
• diarrhea.

In more serious cases, the infection can lead to complications such as

• jaundice,
• kidney damage
• liver damage,
• meningitis,
• respiratory issues,
• hemorrhages.

Pulmonary hemorrhage — acute bleeding from the lungs — can also occur, posing life-threatening risks such as respiratory and renal failure. The illness may last from a few days to several weeks, and without treatment, recovery can take months, according to the US Centers for Disease Control and Prevention (CDC).

What Precautions Should Be Taken?

To reduce the risk of leptospirosis infection, individuals are advised to take several important precautions. According to the CDC, it is essential to avoid wading through dirty rainwater, especially during the rainy season, and to wear gumboots in such conditions.

Proper care of any injuries or cuts is crucial, and frequent handwashing, particularly after handling food or working in potentially contaminated environments, is highly recommended. Additionally, individuals should avoid contact with animals that appear sick or are known carriers of the bacteria.

Vaccination is also vital—pet owners should ensure their pets are vaccinated against leptospirosis, especially if they are frequently exposed to water or wildlife. Staying hydrated by drinking plenty of clean water and preventing water stagnation around the home can further minimize the risk of infection.

The emerging COVID variant, BA 3.2, nicknamed “Cicada,” has revived memories of the COVID-19 pandemic that disrupted the world and raised fresh concerns about the possibility of severe illness.

The variant has been given the nickname “Cicada” due to its reappearance after remaining dormant or undetected for a long period, much like cicadas that emerge after years underground.

With the variant already spread to 23 nations, as of February, experts are urging people to use masks to avoid transmission.

What Is The Cicada COVID Variant?

Cicada was first identified in a respiratory sample in South Africa in November 2024.

It is a descendant of the Omicron BA.3 lineage, and is genetically distinct from the previously circulating JN.1 lineages (including LP.8.1 and XFG).

BA.3.2 comprises two major branches, BA.3.2.1 and BA.3.2.2. BA.3.2.2 also has substitutions like: K356T, A575S, R681H, and R1162P.

The World Health Organization (WHO) has designated BA.3.2 as a Variant Under Monitoring (VUM). It means the variant may not be that dangerous yet, but it may have concerning mutations.

As per the US CDC’s latest Morbidity and Mortality Weekly Report, Cicada has “70 to 75 substitutions and deletions in the gene sequence of its spike protein”.

Time To Mask Up

Dr. Sai Balasubramanian, a doctor and healthcare strategy executive, writing in Forbes, stressed the need to follow COVID practices such as masks and hand hygiene.

"Healthcare professionals recommend taking general precautions, similar to those used to prevent most viral transmission: get vaccinations when appropriate, wear masks in crowded areas or indoors where there is a high risk of transmission," he said.

He also urged “avoid individuals who have known illness or infections, wash hands frequently, and continue to stay apprised of local community guidelines and the infection spread”.

Cicada variant “is different from the (Covid-19) viruses we have been dealing with for the last two years," Prof Ravi Gupta, of Cambridge University, who advised the UK government during the pandemic, was quoted as saying by The Mirror.

Will The Cicada Variant Cause Severe Illness?

The SARS-CoV-2 virus has the potential to turn deadly in people, especially among vulnerable populations such as those with a weak immune system.

The Cicada variant is particularly concerning as it provides no immune protection to people with previous infection or even vaccination.

Yet, the World Health Organization and health experts advise that existing COVID vaccinations can help prevent severe illness and hospitalization.

"It would appear that all the protections we have from our experience with the virus and with vaccines probably offer more limited—not zero—but more limited protection against this strain," Dr. William Schaffner, professor of infectious diseases at Vanderbilt University Medical Center, was quoted as saying by Time.

Cicada Variant: Any New Symptoms?

The symptoms of Cicada aren't different from those of previous COVID variants. These include:

• sore throat,
• fever or chills,
• headache,
• cough,
• body aches,
• runny nose
• nausea
• diarrhea.